GlassScriptPhysician profile
Mitchell W West
NPI 1790346484
$1,129.28
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.63 · 2020: $248 · 2021: $830 · 2024: $27.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.14 | 2021 | |
| Scilex Pharmaceuticals INC. | $226.48 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $85.60 | 2020-2021 | |
| Abbvie INC. | $63.72 | 2021 | |
| Mdd US Operations, LLC | $56.37 | 2021 | |
| Ibsa Pharma INC. | $46.85 | 2021 | |
| Collegium Pharmaceutical, INC. | $44.24 | 2021 | |
| Allergan, INC. | $40.66 | 2021 | |
| Virtus Pharmaceuticals LLC | $40.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.79 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.35 | 2021 | |
| Chiesi USA, INC. | $27.56 | 2024 | Kengreal, Cleviprex |
| Almatica Pharma LLC | $26.63 | 2021 | |
| Organogenesis INC. | $24.90 | 2021 | |
| Vertiflex, INC. | $23.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $16.42 | 2021 | |
| Eisai INC. | $16.28 | 2021 | |
| Abbott Laboratories | $13.39 | 2021 | |
| Pfizer INC. | $11.86 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.